Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions in Q3FY23 showcasing a 3% rise on an YoY basis. In this quarter’s results, the reports suggested that the firm has continued to deliver consistent performance in all key operational and financial indicators in Q3Y23.
Sun Pharmaceutical Q3FY23; 3% Growth in Profits
Tags: Pharmaceutical
Related Post
- NLC India Ltd Q2FY25; 10% fall in Profits
NLC India is engaged in the business of mining of lignite and generation of power…
-
NHPC Ltd Q2FY25; 37% fall in Profits
NHPC, a Mini Ratna category I public sector utility, is Government of India’s flagship hydroelectric…
-
Ashok Leyland Ltd Q2FY25; 35% rise in Profits
Ashok Leyland is the flagship Company of the Hinduja group, having a long-standing presence in…